4.4 Article

Chelating Systems for 99mTc/188Re in the Development of Radiolabeled Peptide Pharmaceuticals

期刊

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
卷 12, 期 5, 页码 428-461

出版社

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/187152012800617821

关键词

Technetium; Rhenium; Peptide; Theragnostic

资金

  1. Ministero dell'Istruzione, dell'Universita e della Ricerca [2008F5A3AF-002]

向作者/读者索取更多资源

Currently, receptor based radiopharmaceuticals have received great attention in molecular imaging and radiotherapy of cancer, and provide a unique tool for target-specific delivery of radionuclides to pathological tissues. In this context, receptor binding peptides represent an attractive class of target vectors for Nuclear Medicine purposes. The rich chemistry of the group 7 elements elaborated in past years, has allowed the development of different procedures for the preparation of radiolabeled peptides in high yield. This, joint to the use of solid-phase peptide synthesis, has opened the possibility to explore new strategies for approaching the design of new class of radiolabeled receptor-targeted peptides, and to create new versatilities in targeting vehicle design e. g. in synthesis of metal-cyclized peptides or of multivalent targeting agents. This review provides an overview on several aspects of the development of new Tc-99m/Re-188-peptide based target specific radiopharmaceuticals, in particular on the synthetic strategies employed for modifying molecular vectors, and the application of the different metal-cores and/or building block for preparing high specific activity agents.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据